News

According to the industry analysts covering BOT, breakeven is near. They anticipate the company to incur a final loss in 2021, before generating positive profits of AU$33m in 2022. Therefore, BOT is expected to breakeven roughly 2 years from today. In order to meet this breakeven date, I calculated the rate at which BOT must grow year-on-year. It turns out an average annual growth rate of 96% is expected, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Click HERE to read the article on Simply Wall Street.

Amid the difficulties created by the COVID-19 pandemic, synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) unveiled an operational boost in the form of support from the US FDA to fast track its first antibacterial product BTX 1801.

Earlier today, the company announced that the FDA’s Office of Antimicrobial Products had granted BTX 1801 – a treatment to prevent post-surgical infections – what’s known as qualified infectious disease product (QIDP) status which means Botanix can receive a variety of incentives as part of its drug development program.

Click HERE to read the article on SmallCaps.